Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The companys Phase III product candidates include liprotamase or Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, and others. It also develops Blisibimod, which is in Phase II clinical study for the treatment of Immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, California.